WO2000037043A1 - Schäumende antacida-suspensionstabletten - Google Patents
Schäumende antacida-suspensionstabletten Download PDFInfo
- Publication number
- WO2000037043A1 WO2000037043A1 PCT/EP1999/009934 EP9909934W WO0037043A1 WO 2000037043 A1 WO2000037043 A1 WO 2000037043A1 EP 9909934 W EP9909934 W EP 9909934W WO 0037043 A1 WO0037043 A1 WO 0037043A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mixture
- antacid
- acid
- gel
- swelling
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Definitions
- the invention relates to preparations which contain one or more acid-binding active ingredients (antacid), a method for producing these preparations and their use as medicaments for regulating the hyperacidity of the stomach.
- antacids are used for the symptomatic therapy of duodenal and ventricular ulcers as well as for heartburn and acid-related stomach problems, such as hyperacid gastritis.
- the effect of the antacids is essentially based on the fact that the gastric hydrochloric acid is partially buffered, so that the pH of the stomach increases from 1 to 2 to 3 to 4. This increase in pH can reduce or even alleviate the symptoms typical of hyperacidity, such as a feeling of fullness or heartburn.
- antacids are in powder form, as normal tablets, predominantly as Chewable tablets or as suspensions in bottles or packaged in sachets. German patent application DE 44 24 676 also describes antacid effervescent tablets.
- the known chewable tablets can be dosed very easily and simply, but have the disadvantage that the patients perceive them as sandy and thus uncomfortable after chewing.
- the well-known finely dispersed suspension pharmaceutical forms do not feel sandy, are well tolerated and are also characterized by a rapid and clearly noticeable onset and effect.
- a disadvantage of these suspension pharmaceutical forms is, however, the fact that older patients in particular have difficulty in removing the suspensions completely and without major difficulties from the sachet packs.
- the dosage and administration of effervescent tablets is easier, but the previous effervescent tablets require a glass of water in which the effervescent tablets dissolve into a liquid drinkable suspension while effervescing. As a result, taking the drug is not possible at every opportunity.
- all forms of antacid preparation available so far have certain disadvantages when administered.
- the invention has for its object to provide an antacid preparation with which a good and fast-acting suspension can be produced in the same fine dispersity as possible, for example preferably by chewing and salivating, the antacid preparation being easier, safer and easier to apply at the same time is as the antacid formulations known from the prior art. This object is achieved by the features listed in the claims.
- the invention relates to antacid chewable tablets that develop a foam gel when chewed in the mouth.
- Such tablets can be manufactured so that they can still be easily chewed by older patients.
- Chewable tablets allow a satisfactory dosage of the active ingredient, are easy to remove from their packaging and do not require any liquid to be taken.
- the novel tablets according to the invention develop a foaming suspension gel which is perceived as pleasant in the mouth and which can be swallowed without problems. In the stomach, this highly dispersed foam gel leads to surprisingly good buffering.
- the invention relates to an antacid preparation which comprises the following components:
- Acid-binding active ingredients for antacid preparations are known to the person skilled in the art.
- magnesium hydroxide, magnesium oxide, magnesium carbonate, magnesium silicate, aluminum hydroxide, aluminum phosphate and magnesium aluminum silicate or mixtures thereof can be used as acid binding agents.
- Aluminum hydroxide, magnesium hydroxide, hydrotalcite or magaldrate, a magnesium aluminum silicate, are preferred. Magaldrat is particularly preferred.
- the person skilled in the art knows from DE 44 24 676 that aluminum-containing medicaments can have a toxic effect under certain conditions, in particular if the aluminum compound is combined with certain acids, such as Citric acid.
- the person skilled in the art will therefore depend on the overall composition of the antacid preparation and, for example, will not use aluminum compounds or use them in lower doses if another component of the preparation according to the invention is citric acid, or the person skilled in the art Conversely, citric acid is not used or is used only in small quantities if the preparation is to contain an aluminum compound.
- the acid-binding active ingredients are used in a concentration of 20 to 80% by weight, preferably 40 to 75% by weight, more preferably 50 to 70% by weight, based on the total dry weight of the preparation.
- the C0 2 developing effervescent mixture used comprises an acid component and a basic component.
- Acidic components of the effervescent mixture developing CO 2 are, for example, citric acid, tartaric acid, adipic acid, ascorbic acid, malic acid, fumaric acid and maleic acid as well as acidic salts, for example potassium bitartrate, primary sodium phosphate, primary sodium citrate, primary sodium tartrate or mixtures thereof.
- Citric acid, tartaric acid, adipic acid and primary sodium citrate are preferred, citric acid, tartaric acid and primary sodium citrate are particularly preferred.
- Suitable acid components of the C0 2 developing effervescent mixture are acidic salts of basic amino acids, such as glycine, alanine, valine, ornithine or lysine.
- C0 2- developing compounds are generally suitable, in particular sodium hydrogen carbonate, sodium carbonate, calcium carbonate or mixtures thereof.
- the ratio of the acidic component of the C0 2 developing shower mixture to the basic component of the C0 2 developing shower mixture is usually equimolecular / stoichiometric.
- the proportion of effervescent mixtures developing CO 2 in the total dry weight of the antacid preparation is 5 to 50% by weight, preferably 7.5 to 25% by weight, most preferably 10 to 20% by weight.
- the components of the effervescent mixture are preferably calculated so stoichiometrically that the foam suspension gel formed with the other components and the saliva in the mouth is weakly alkaline responds.
- Weakly alkaline means a pH of 7 to 9, preferably 7 to 8.
- the CO 2 developing effervescent mixtures in the foaming suspension tablets according to the invention are basically dosed much lower than in effervescent tablets. They should not result in a liquid suspension, but rather an easy-to-swallow foam gel, which releases the active ingredients in the stomach quickly and finely dispersed over large areas of the gastric mucosa.
- the polymeric, foam-forming surfactant ("foaming agent") which can be used for the preparations according to the invention are, in particular, the well-tolerated polymeric surfactants, such as, for example, the poloxamers (block copolymers of ethylene oxide and propylene oxide), or other non-toxic polymeric surfactants with molecular weights above 3000.
- Particularly preferred are Pluronic ® F 68 or Pluronic ® F 127 (BASF AG, Ludwigshafen / Rh. Or Wyandotte Chem. Corp., Biddle, Wyandotte, Michigan) that are hemolytic (blood cells destructive) or only to a small extent.
- the content of the form-forming polymeric ten- Side in the preparation is 0.5 to 30% by weight, preferably 1 to 20% by weight, most preferably 3 to 10% by weight, based on the total dry weight of the preparation.
- Polysaccharides and polysaccharide derivatives or polyacrylic acids are particularly suitable as swelling and gel-forming polymer.
- polysaccharides and polysaccharide derivatives are tragacanth, galactomannan, cellulose ethers, for example methyl cellulose and mixed cellulose ethers, such as hydroxypropyl or hydroxybutyl methyl cellulose. Such methyl cellulose and mixed cellulose ethers are marketed by Dow Chemical under the brand name Methocel.
- polyacrylic acids which can be used according to the invention are Carbopol or Eudispert (pharmaceutically customary or approved Carbapol and Eudisper types).
- the proportion of the swelling, gel-forming polymers in the total dry weight of the preparation is 3 to 30%, preferably 5 to 15%, most preferably 7.5 to 10%.
- the antacid preparation generally contains a residual moisture content of not more than 6%, preferably not more than 3%, most preferably not more than 1%, based on the total weight of the preparation.
- the antacid preparation can also contain customary tablet auxiliaries, such as sugar alcohols or sugar (glucose, lactose, etc.) as fillers, sweeteners, flavoring agents, and lubricants, mold release agents and flow regulators.
- the preparation according to the invention is suitable for use as an antacid, that is to say as a medicament for regulating the hyperacidity of the stomach.
- the preparations according to the invention can in particular be formulated in the form of a chewable tablet.
- other forms of administration are also possible, such as administration in the form of a powder or granules.
- the invention further provides a method for producing a preparation as defined above, which comprises the following steps:
- the swelling, gel-forming polymer is homogeneously admixed in at least one of steps (i), (ii) or (iv), and in which case customary tablet auxiliaries can optionally be added in the individual process steps.
- the acid-binding active ingredient or a mixture of these active ingredients is homogeneously mixed with the basic constituent of the brewing mixture which releases CO 2 . If necessary, a swelling, gel-forming polymer or a mixture of several of these polymers can be added at this stage.
- the homogeneous mixing can preferably be carried out by an intensive mixer or mixer kneader.
- an aqueous solution of the foaming agent for example an aqueous solution of Pluronic F 68 or Pluronic F 127
- aqueous solution of Pluronic F 68 or Pluronic F 127 is produced as stage (ii).
- Water or an aqueous surfactant or sweetener solution for example poloxane or saccharin solution, can be used as the aqueous solvent.
- aqueous surfactant or sweetener solution for example poloxane or saccharin solution
- the amount of water used is preferably just so high that the mass in question becomes moist plastic and can be granulated sufficiently well.
- the aqueous solution of the foaming agent can optionally be a swelling, gel-forming polymer or gel Mixtures of these are added.
- a homogeneous suspension is produced by stirring.
- stage (iii) the homogeneous mixture obtained in stage (i) from the acid-binding active ingredient or mixtures thereof and the basic constituent of the CO 2 -releasing effervescent mixture, which optionally additionally contains one or more swelling gel-forming polymers, with the stage (ii ) obtained aqueous solution of the foaming agent or the aqueous suspension of the foaming agent and the swelling gel-forming polymer or mixtures thereof combined and mixed.
- a mixer or kneader with stirring or kneading tools is used to mix these components.
- the mixture obtained is granulated wet. Moist granulation is carried out by adding moisture to a moisture-plastic and thus granulable consistency.
- the granules obtained are dried.
- the drying is dried to a residual moisture content of 0.1 to 6.0%, preferably 1 to 3%, most preferably ⁇ 1.0%.
- Conventional drying devices such as drying cabinets and fluidized bed dryers can be used as dryers. Suitable dryers are described, for example, in Bauer, Frömming, 5.3, "Pharmaceutical Technology", G. Fischer Verlag, Stuttgart, Jena, 5th edition, 1997, pages 123 to 130.
- Pre-drying is preferably carried out at temperatures from 30 to 70 ° C., more preferably 40 to 60 ° C., most preferably 45 to 50 ° C.
- the dried granules are then sieved.
- the usual sieves are sieves which are used, for example, in Bauer, Frömming, 5.3, "Pharmaceutical Technology", G. Fischer Verlag, Stuttgart, Jena, 5th edition, 1997, page 108 (sieves).
- Suitable sieves have a mesh size of 0.1 to 3.0 mm, preferably 0.5 to 1.5 mm. Sieving takes place at normal pressure or, if necessary, using excess pressure.
- the suitable mesh sizes depend on the desired or required dispersity or homogeneity.
- a homogeneous dry mixture is produced from the acidic component of the CO 2 developing effervescent mixture and optionally one of the several swelling gel polymers.
- the same device described for the first stage of the process can be used to produce this homogeneous dry mixture.
- the mixture obtained in stage (iv) from the acidic constituent of the CO 2 developing effervescent mixture and, if appropriate, one or more gel-forming polymers is admixed with the granules obtained in the third stage.
- the same equipment as that described for the first stage can be used.
- the granules thus obtained can then be compressed into chewable tablets, for example.
- the tablets are preferably pressed so hard that they can be packaged well and are still easy to chew.
- the known rotary and eccentric tablet presses can be used as tableting devices.
- the hardness of the chewing foam gel tablets should preferably be 4 to 7 kp.
- customary tablet auxiliaries such as, for example, can be used in each of the stages auxiliaries defined above are added.
- the swelling, gel-forming polymer must be mixed in at least one of steps (i), (ii) or (iv).
- the swelling, gel-forming polymer is added in steps (ii) and (iv).
- the swelling, gel-forming polymer is added only at step (i).
- the swelling, gel-forming polymer is only added in step (iv). It is important to ensure that acidic and basic substances are mixed in such a way or in a state that they cannot react prematurely or unintentionally. This is done, for example, by granulating them separately and only missing them in a dry, non-reactive state.
- the preparations produced by the process according to the invention can be formulated in the form of a chewable tablet.
- the highly dispersed foam gel that forms after chewing in the mouth in conjunction with saliva, as shown in FIG. 1 leads to a surprisingly rapid buffering.
- the buffer capacities are between those of a normal aluminum hydroxide gel / magnesium hydroxide gel suspension and a normal aluminum hydroxide gel / magnesium hydroxide gel tablet.
- FIG. 1 shows the determination of the buffer capacity by the direct titration of selected antacid preparations with 0.1 N HC1 in ml / sec.
- the buffer capacity of a commercially available antacid suspension, a commercially available antacid tablet and a foaming antacid suspension tablet according to the invention were compared with one another. All preparations contained the same amount of active ingredient. The buffer capacity was determined by direct titration of the preparations mentioned with 0.1 N HCl. The experiment shows that the foaming antacid suspension according to the invention buffer acid much better than conventional tablets. Conventional liquid suspensions have the highest overall buffer capacity, the suspensions initially buffering more slowly than the foaming antacid suspension tablets according to the invention. The results of this experiment are shown graphically in FIG. 1.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002355627A CA2355627A1 (en) | 1998-12-21 | 1999-12-14 | Foaming antacid suspension tablets |
AU22835/00A AU2283500A (en) | 1998-12-21 | 1999-12-14 | Foaming antacid suspension tablets |
US09/868,556 US6589507B1 (en) | 1998-12-21 | 1999-12-14 | Foaming antacid suspension tablets |
AT99966965T ATE249812T1 (de) | 1998-12-21 | 1999-12-14 | Schäumende antacida-suspensionstabletten |
DE59907057T DE59907057D1 (de) | 1998-12-21 | 1999-12-14 | Schäumende antacida-suspensionstabletten |
DK99966965T DK1140013T3 (da) | 1998-12-21 | 1999-12-14 | Skummende antacida-suspensionstabletter |
SI9930445T SI1140013T1 (en) | 1998-12-21 | 1999-12-14 | Foaming antacid suspension tablets |
JP2000589154A JP2002532533A (ja) | 1998-12-21 | 1999-12-14 | 気泡性制酸性懸濁錠剤 |
EP99966965A EP1140013B1 (de) | 1998-12-21 | 1999-12-14 | Schäumende antacida-suspensionstabletten |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19859231A DE19859231A1 (de) | 1998-12-21 | 1998-12-21 | Schäumende Antacida-Suspensionstabletten |
DE19859231.0 | 1998-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000037043A1 true WO2000037043A1 (de) | 2000-06-29 |
Family
ID=7892092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1999/009934 WO2000037043A1 (de) | 1998-12-21 | 1999-12-14 | Schäumende antacida-suspensionstabletten |
Country Status (11)
Country | Link |
---|---|
US (1) | US6589507B1 (de) |
EP (1) | EP1140013B1 (de) |
JP (1) | JP2002532533A (de) |
AT (1) | ATE249812T1 (de) |
AU (1) | AU2283500A (de) |
CA (1) | CA2355627A1 (de) |
DE (2) | DE19859231A1 (de) |
DK (1) | DK1140013T3 (de) |
ES (1) | ES2209551T3 (de) |
PT (1) | PT1140013E (de) |
WO (1) | WO2000037043A1 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004006945A1 (ja) * | 2002-07-12 | 2004-01-22 | Tsumura & Co. | 漢方エキス含有錠剤組成物およびその製造方法 |
WO2004029057A1 (ja) * | 2002-09-25 | 2004-04-08 | Sankyo Company, Limited | 内臓痛の治療または予防のための医薬組成物 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19962251A1 (de) * | 1999-12-22 | 2001-09-06 | Hermes Fabrik Pharm Praeparate | Lutschtablette |
US20050220865A1 (en) * | 2004-04-02 | 2005-10-06 | Koleng John J | Compressed composition comprising magnesium salt |
EP1757268B1 (de) * | 2004-06-07 | 2017-07-05 | Kureha Corporation | Zusammensetzung in trockener form zur oralen einnahme und zusammensetzung in gelform zur oralen einnahme, die zum zeitpunkt der verwendung bereitet wird |
ES2390781T3 (es) * | 2004-10-13 | 2012-11-16 | Kraft Foods Global Brands Llc | Composiciones de comprimidos masticables efervescentes |
EP1865790A1 (de) * | 2005-02-25 | 2007-12-19 | Cadbury Adams USA LLC | Essbare zusammensetzungen mit gelierenden silikaten |
GB0515492D0 (en) * | 2005-07-28 | 2005-08-31 | Reckitt Benckiser Healthcare | Improvements in or relating to compositions,articles and methods |
ES2442692T3 (es) * | 2005-08-02 | 2014-02-12 | Intercontinental Great Brands Llc | Confite masticable recubierto |
FR2928269B1 (fr) * | 2008-03-05 | 2011-10-07 | Innothera Chouzy | Formulation pharmaceutique orale sous forme unitaire de comprime soluble ou dispersible, notamment effervescent, appropriee a une fabrication par compression |
EP2649989B1 (de) | 2012-04-13 | 2017-10-18 | King Saud University | Verfahren zur Herstellung einer Feststoffdispersion, damit hergestellte Feststoffdispersion und Verwendung dafür |
BR112014030680B1 (pt) | 2012-06-12 | 2022-08-30 | The Procter & Gamble Company | Forma de dosagem mastigável efervescente |
US20140371174A1 (en) | 2013-06-12 | 2014-12-18 | The Procter & Gamble Company | Effervescent Dosage Form |
FR3036961B1 (fr) * | 2015-06-03 | 2019-05-24 | Densmore Et Cie | Complement alimentaire comprenant un melange d'oxyde de magnesium et de carbonate de magnesium |
CA2999411A1 (en) * | 2015-10-01 | 2017-04-06 | Apharm S.R.L. | Combination of glycosaminoglycans and an antacid agent and compositions thereof |
CN105663073A (zh) * | 2016-04-06 | 2016-06-15 | 刘建军 | 以粘合剂泡沫状态制粒的中药片剂的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4613497A (en) * | 1984-02-29 | 1986-09-23 | Health Products Development, Inc. | Dry, water-foamable pharmaceutical compositions |
US4716033A (en) * | 1986-03-27 | 1987-12-29 | Warner-Lambert Company | Medicament adsorbates with surfactant and their preparation |
US4783331A (en) * | 1987-06-29 | 1988-11-08 | Miles Inc. | Method for solubilization of aspartame in effervescent aqueous systems; and composition |
US5330760A (en) * | 1992-08-27 | 1994-07-19 | Sterling Winthrop Inc. | Effervescent antacid |
-
1998
- 1998-12-21 DE DE19859231A patent/DE19859231A1/de not_active Withdrawn
-
1999
- 1999-12-14 EP EP99966965A patent/EP1140013B1/de not_active Expired - Lifetime
- 1999-12-14 AT AT99966965T patent/ATE249812T1/de not_active IP Right Cessation
- 1999-12-14 CA CA002355627A patent/CA2355627A1/en not_active Abandoned
- 1999-12-14 AU AU22835/00A patent/AU2283500A/en not_active Abandoned
- 1999-12-14 ES ES99966965T patent/ES2209551T3/es not_active Expired - Lifetime
- 1999-12-14 DE DE59907057T patent/DE59907057D1/de not_active Expired - Fee Related
- 1999-12-14 JP JP2000589154A patent/JP2002532533A/ja not_active Withdrawn
- 1999-12-14 DK DK99966965T patent/DK1140013T3/da active
- 1999-12-14 WO PCT/EP1999/009934 patent/WO2000037043A1/de active IP Right Grant
- 1999-12-14 PT PT99966965T patent/PT1140013E/pt unknown
- 1999-12-14 US US09/868,556 patent/US6589507B1/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4613497A (en) * | 1984-02-29 | 1986-09-23 | Health Products Development, Inc. | Dry, water-foamable pharmaceutical compositions |
US4716033A (en) * | 1986-03-27 | 1987-12-29 | Warner-Lambert Company | Medicament adsorbates with surfactant and their preparation |
US4783331A (en) * | 1987-06-29 | 1988-11-08 | Miles Inc. | Method for solubilization of aspartame in effervescent aqueous systems; and composition |
US5330760A (en) * | 1992-08-27 | 1994-07-19 | Sterling Winthrop Inc. | Effervescent antacid |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004006945A1 (ja) * | 2002-07-12 | 2004-01-22 | Tsumura & Co. | 漢方エキス含有錠剤組成物およびその製造方法 |
US7326427B2 (en) | 2002-07-12 | 2008-02-05 | Tsumura & Co. | Tablet composition containing Kampo medicinal extract and its manufacturing process |
CN100546655C (zh) * | 2002-07-12 | 2009-10-07 | 株式会社津村 | 含有中药提取物的片剂组合物及其制造方法 |
WO2004029057A1 (ja) * | 2002-09-25 | 2004-04-08 | Sankyo Company, Limited | 内臓痛の治療または予防のための医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
DE59907057D1 (de) | 2003-10-23 |
EP1140013A1 (de) | 2001-10-10 |
PT1140013E (pt) | 2004-02-27 |
US6589507B1 (en) | 2003-07-08 |
JP2002532533A (ja) | 2002-10-02 |
CA2355627A1 (en) | 2000-06-29 |
DK1140013T3 (da) | 2004-01-26 |
ES2209551T3 (es) | 2004-06-16 |
EP1140013B1 (de) | 2003-09-17 |
AU2283500A (en) | 2000-07-12 |
ATE249812T1 (de) | 2003-10-15 |
DE19859231A1 (de) | 2000-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69821553T2 (de) | Granulatzubereitung enthaltend Simethicon und granuliertes wasserfreies Calciumphosphat | |
DE60028536T2 (de) | In der Mundhöhle schnell zerfallende orale feste Verabreichungsform | |
EP1140013B1 (de) | Schäumende antacida-suspensionstabletten | |
EP1067905B1 (de) | Brauseformulierungen | |
DE3246492C2 (de) | Verfahren zur Herstellung therapeutischer Präparate auf der Basis von Hydroxypropylmethylzellulose mit verlängertem Freisetzungsverlauf | |
AT394948B (de) | Pharmazeutischer traegerstoff zur dauerabgabe von arzneimitteln mit einem gehalt an celluloseaethern und carboxyvinylpolymer | |
US5188839A (en) | Pharmaceutical compositions of cimetidine | |
DE69233239T2 (de) | Pharmazeutische Granulate mit intragranularem Sprengmittel | |
DE69333927T2 (de) | Agglomerierte hydrophile Komplexe mit mehrphasigen Abgabeeigenschaften | |
EP0486863B1 (de) | Antazida-Zubereitung mit verlängerter Magenverweilzeit | |
EP0476696B1 (de) | Pharmazeutische Zubereitung mit verbessertem Geschmack, poröse Partikel enthaltend, und deren Herstellungsmethode | |
US5275823A (en) | Pharmaceutical compositions | |
EP1410793B1 (de) | Darreichungsform von Ibuprofen-Natrium | |
DE69814850T2 (de) | Paracetamol enthaltende schlickbare tablette | |
DE4406424A1 (de) | Expandierbare Arzneiformen | |
JPH05112445A (ja) | 作用開始を速くし潜在特性を増加させる移送システム | |
EP0582186A1 (de) | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung | |
KR20130030306A (ko) | 약학 조성물 | |
EP0759296B1 (de) | Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz | |
DE2332484A1 (de) | Lutschpastillen mit verzoegerter freigabe | |
DE4444052A1 (de) | Pharmazeutische, oral anwendbare Zubereitung | |
DE60300862T2 (de) | Verbesserungen an oder in bezug auf arzneizusammensetzungen | |
CH674148A5 (de) | ||
DE69831940T2 (de) | Tablette mit verlängerter Wirkstoffabgabe im Magen | |
EP2515852B1 (de) | Oral dispersible tablette enthaltend kompaktierte sildenafil-base |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2355627 Country of ref document: CA Ref country code: CA Ref document number: 2355627 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 589154 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999966965 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09868556 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999966965 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999966965 Country of ref document: EP |